These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18212102)

  • 1. Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
    Dekhtyar T; Ng TI; Lu L; Masse S; DeGoey DA; Flosi WJ; Grampovnik DJ; Klein LL; Kempf DJ; Molla A
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1337-44. PubMed ID: 18212102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
    Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
    Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.
    Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A
    J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
    Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA
    J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.
    Doyon L; Tremblay S; Bourgon L; Wardrop E; Cordingley MG
    Antiviral Res; 2005 Oct; 68(1):27-35. PubMed ID: 16122817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
    Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
    AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
    Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
    J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
    Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
    Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
    Tojo Y; Koh Y; Amano M; Aoki M; Das D; Kulkarni S; Anderson DD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3460-70. PubMed ID: 20439612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
    Dandache S; Sévigny G; Yelle J; Stranix BR; Parkin N; Schapiro JM; Wainberg MA; Wu JJ
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4036-43. PubMed ID: 17638694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
    Schmit JC; Ruiz L; Clotet B; Raventos A; Tor J; Leonard J; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 1996 Aug; 10(9):995-9. PubMed ID: 8853733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
    BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
    Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
    J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.